BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 12018106)

  • 1. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese.
    Hamajima N; Matsuo K; Iwata H; Shinoda M; Yamamura Y; Kato T; Hatooka S; Mitsudomi T; Suyama M; Kagami Y; Ogura M; Ando M; Sugimura Y; Tajima K
    Int J Clin Oncol; 2002 Apr; 7(2):103-8. PubMed ID: 12018106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
    Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.
    Ergen HA; Gormus U; Narter F; Zeybek U; Bulgurcuoglu S; Isbir T
    Anticancer Res; 2007; 27(6B):4107-10. PubMed ID: 18225579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer.
    Harth V; Donat S; Ko Y; Abel J; Vetter H; BrĂ¼ning T
    Arch Toxicol; 2000 Jan; 73(10-11):528-31. PubMed ID: 10663383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association between Helicobacter pylori seropositivity and ornithine decarboxylase (ODC) A317G polymorphism, and no modification by NAD(P)H:qinone oxidoreductase 1 (NQO1) C609T.
    Goto Y; Nishio K; Ishida Y; Kawai S; Osafune T; Naito M; Katsuda N; Hamajima N
    Nagoya J Med Sci; 2007 Jan; 69(1-2):17-22. PubMed ID: 17378176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
    Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
    Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].
    Zhang JH; Li Y; Wang R; Sarbia M; Guo W; Wen DG; Wei LZ; Chen ZF; Kuang G; Zhang LW; He M; Wu ML; Wang SJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):544-6. PubMed ID: 14669229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer.
    Begleiter A; Hewitt D; Maksymiuk AW; Ross DA; Bird RP
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2422-6. PubMed ID: 17164365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects.
    Niwa Y; Hirose K; Nakanishi T; Nawa A; Kuzuya K; Tajima K; Hamajima N
    Gynecol Oncol; 2005 Feb; 96(2):423-9. PubMed ID: 15661231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.
    Lyn-Cook BD; Yan-Sanders Y; Moore S; Taylor S; Word B; Hammons GJ
    Cell Biol Toxicol; 2006 Mar; 22(2):73-80. PubMed ID: 16532285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An association between a NQO1 genetic polymorphism and risk of lung cancer.
    Saldivar SJ; Wang Y; Zhao H; Shao L; Lin J; Spitz MR; Wu X
    Mutat Res; 2005 Apr; 582(1-2):71-8. PubMed ID: 15781212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer.
    van der Logt EM; Bergevoet SM; Roelofs HM; Te Morsche RH; Dijk Yv; Wobbes T; Nagengast FM; Peters WH
    Mutat Res; 2006 Jan; 593(1-2):39-49. PubMed ID: 16039674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.
    Fowke JH; Shu XO; Dai Q; Jin F; Cai Q; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1308-15. PubMed ID: 15298951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior.
    Xu LL; Wain JC; Miller DP; Thurston SW; Su L; Lynch TJ; Christiani DC
    Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):303-9. PubMed ID: 11319169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.
    Lafuente MJ; Casterad X; Trias M; Ascaso C; Molina R; Ballesta A; Zheng S; Wiencke JK; Lafuente A
    Carcinogenesis; 2000 Oct; 21(10):1813-9. PubMed ID: 11023538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study on the relationship between polymorphism of human NAD(P)H: quinone oxidoreductase and Parkinson's disease in Chinese].
    Jiang XH; Yang H; Yang JF; Wang HT; Xu QY; Chen B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):120-3. PubMed ID: 15079792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
    Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
    Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of fruit and vegetable consumption and genetic variation on NAD(P)H:quinone oxidoreductase (NQO1) phenotype in an endoscopy-based population.
    Tijhuis MJ; Boerboom AM; Visker MH; Op den Camp L; Nagengast FM; Tan AC; Rietjens IM; Kok FJ; Aarts JM; Kampman E
    Nutr Cancer; 2008; 60(2):204-15. PubMed ID: 18444152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
    Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
    Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients.
    Masroor M; Jain A; Javid J; Mir R; Prashant Y; Imtiyaz A; Mariyam Z; Mohan A; Ray PC; Saxena A
    Asian Pac J Cancer Prev; 2015; 16(17):7653-8. PubMed ID: 26625776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.